Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
How to buy Teva Pharmaceutical Industries stock
Learn how to easily invest in Teva Pharmaceutical Industries stock.
Teva Pharmaceutical Industries Limited is a drug manufacturers-specialty & generic business based in the US. Teva Pharmaceutical Industries shares (TEVA) are listed on the NYSE and all prices are listed in US Dollars. Teva Pharmaceutical Industries employs 37,100 staff and has a trailing 12-month revenue of around 0.00.
How to buy shares in Teva Pharmaceutical Industries
- Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
- Open your brokerage account. Complete an application with your details.
- Confirm your payment details. Fund your account.
- Research the stock. Find the stock by name or ticker symbol – TEVA – and research it before deciding if it's a good investment for you.
- Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
- Check in on your investment. Optimize your portfolio by tracking your stock.
What's in this guide?
- TEVA shares summary
- Compare share dealing platforms
- Is TEVA stock a buy or sell?
- Stock performance over time
- Is TEVA suitable for ethical investing?
- Are TEVA shares over-valued?
- Teva Pharmaceutical Industries's financials
- How volatile are TEVA shares?
- Does Teva Pharmaceutical Industries pay a dividend?
- Have TEVA shares ever split?
- Other common questions
Teva Pharmaceutical Industries stock price (NYSE: TEVA)Use our graph to track the performance of TEVA stocks over time.
Teva Pharmaceutical Industries shares at a glance
|Latest market close||$9.17|
|52-week range||$7.73 - $13.30|
|50-day moving average||$8.66|
|200-day moving average||$9.66|
|Wall St. target price||$11.36|
|Dividend yield||$0 (0%)|
|Earnings per share (TTM)||$0.66|
Buy Teva Pharmaceutical Industries shares from these brokeragesCompare special offers, low fees and a wide range of types of investments among top trading platforms.
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
Is it a good time to buy Teva Pharmaceutical Industries stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Teva Pharmaceutical Industries price performance over time
|1 week (2022-01-06)||7.63%|
|1 month (2021-12-16)||11.83%|
|3 months (2021-10-14)||-5.46%|
|6 months (2021-07-16)||6.50%|
|1 year (2021-01-15)||-23.33%|
|2 years (2020-01-17)||-10.10%|
|3 years (2019-01-17)||18.76|
|5 years (2017-01-17)||33.75|
Is Teva Pharmaceutical Industries stock undervalued or overvalued?
Valuing Teva Pharmaceutical Industries stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Teva Pharmaceutical Industries's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Teva Pharmaceutical Industries's P/E ratio
Teva Pharmaceutical Industries's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 13x. In other words, Teva Pharmaceutical Industries shares trade at around 13x recent earnings.
That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.
Teva Pharmaceutical Industries's PEG ratio
Teva Pharmaceutical Industries's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 0.7357. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Teva Pharmaceutical Industries's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
Teva Pharmaceutical Industries's EBITDA
Teva Pharmaceutical Industries's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $4.3 billion.
The EBITDA is a measure of a Teva Pharmaceutical Industries's overall financial performance and is widely used to measure a its profitability.
Teva Pharmaceutical Industries financials
|Revenue TTM||$16.2 billion|
|Operating margin TTM||17.81%|
|Gross profit TTM||$7.7 billion|
|Return on assets TTM||3.7%|
|Return on equity TTM||6.99%|
|Market capitalisation||$9.8 billion|
TTM: trailing 12 months
Teva Pharmaceutical Industries's environmental, social and governance track record
Environmental, social and governance (known as ESG) criteria are a set of three factors used to measure the sustainability and social impact of companies like Teva Pharmaceutical Industries.
When it comes to ESG scores, lower is better, and lower scores are generally associated with lower risk for would-be investors.
Teva Pharmaceutical Industries's total ESG risk score
Total ESG risk: 58.8
Socially conscious investors use ESG scores to screen how an investment aligns with their worldview, and Teva Pharmaceutical Industries's overall score of 58.8 (as at 12/31/2018) is pretty weak – landing it in it in the 76th percentile of companies rated in the same sector.
ESG scores are increasingly used to estimate the level of risk a company like Teva Pharmaceutical Industries is exposed to within the areas of "environmental" (carbon footprint, resource use etc.), "social" (health and safety, human rights etc.), and "governance" (anti-corruption, tax transparency etc.).
Teva Pharmaceutical Industries's environmental score
Environmental score: 77.02/100
Teva Pharmaceutical Industries's environmental score of 77.02 puts it squarely in the 87th percentile of companies rated in the same sector. This could suggest that Teva Pharmaceutical Industries is a laggard in its sector in terms of its environmental impact, and exposed to a greater level of risk.
Teva Pharmaceutical Industries's social score
Social score: 47.2/100
Teva Pharmaceutical Industries's social score of 47.2 puts it squarely in the 58th percentile of companies rated in the same sector. This could suggest that Teva Pharmaceutical Industries is pretty average in terms of looking after its workforce and social impact.
Teva Pharmaceutical Industries's governance score
Governance score: 65.26/100
Teva Pharmaceutical Industries's governance score puts it squarely in the 81st percentile of companies rated in the same sector. That could suggest that Teva Pharmaceutical Industries is a laggard in its sector in terms of responsible leadership, and exposed to a greater level of risk.
Teva Pharmaceutical Industries's controversy score
Controversy score: 3/5
ESG scores also evaluate any incidences of controversy that a company has been involved in. Teva Pharmaceutical Industries scored a 3 out of 5 for controversy – a middle-of-the-table result reflecting that Teva Pharmaceutical Industries hasn't always managed to keep its nose clean.
Environmental, social, and governance (ESG) summary
|Total ESG score||58.8|
|Total ESG percentile||76.26|
|Environmental score percentile||87.16|
|Social score percentile||58.24|
|Governance score percentile||80.64|
|Level of controversy||3|
Teva Pharmaceutical Industries share dividends
We're not expecting Teva Pharmaceutical Industries to pay a dividend over the next 12 months.
Have Teva Pharmaceutical Industries's shares ever split?
Teva Pharmaceutical Industries's shares were split on a 2:1 basis on 30 June 2004. So if you had owned 1 share the day before before the split, the next day you'd have owned 2 shares. This wouldn't directly have changed the overall worth of your Teva Pharmaceutical Industries shares – just the quantity. However, indirectly, the new 50% lower share price could have impacted the market appetite for Teva Pharmaceutical Industries shares which in turn could have impacted Teva Pharmaceutical Industries's share price.
Teva Pharmaceutical Industries share price volatility
Over the last 12 months, Teva Pharmaceutical Industries's shares have ranged in value from as little as $7.73 up to $13.3. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NYSE average) beta is 1, while Teva Pharmaceutical Industries's is 1.3001. This would suggest that Teva Pharmaceutical Industries's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Teva Pharmaceutical Industries overview
Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, and internationally. The company offers sterile products, hormones, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments, and creams. It also develops, manufactures, and sells active pharmaceutical ingredients. In addition, it focuses on the central nervous system, pain, respiratory, and oncology areas. Its products in the central nervous system and pain area include Copaxone for the treatment of relapsing forms of multiple sclerosis; AJOVY for the preventive treatment of migraine; and AUSTEDO for the treatment of tardive dyskinesia and chorea associated with Huntington disease. The company's products in the respiratory market comprise ProAir, QVAR, ProAir Digihaler, AirDuo Digihaler, and ArmonAir Digihaler, BRALTUS, CINQAIR/CINQAERO, DuoResp Spiromax, and AirDuo RespiClick/ArmonAir RespiClick for the treatment of asthma and chronic obstructive pulmonary disease. Its products in the oncology market include Bendeka, Treanda, Granix, Trisenox, Lonquex, and Tevagrastim/Ratiograstim.
Teva Pharmaceutical Industries in the news
Hedge Funds Are Avoiding Teva Pharmaceutical Industries (TEVA)
Supreme Court vaccine mandate ruling won't bar companies from demanding Covid shots for workers — Biden vows to advocate for that
March 4th Options Now Available For Teva Pharmaceutical Industries
Frequently asked questionsWhat percentage of Teva Pharmaceutical Industries is owned by insiders or institutions?
Currently 1.285% of Teva Pharmaceutical Industries shares are held by insiders and 47.995% by institutions. How many people work for Teva Pharmaceutical Industries?
Latest data suggests 37,100 work at Teva Pharmaceutical Industries. When does the fiscal year end for Teva Pharmaceutical Industries?
Teva Pharmaceutical Industries's fiscal year ends in December. Where is Teva Pharmaceutical Industries based?
Teva Pharmaceutical Industries's address is: 124 Dvora Hanevi?a Street, Tel Aviv, Israel, 6944020 What is Teva Pharmaceutical Industries's ISIN number?
Teva Pharmaceutical Industries's international securities identification number is: US8816242098 What is Teva Pharmaceutical Industries's CUSIP number?
Teva Pharmaceutical Industries's Committee on Uniform Securities Identification Procedures number is: 881624209
More guides on Finder
Can Turo’s IPO do better than Uber and Airbnb?
Car-sharing service Turo has filed plans for an IPO. What you need to know.
Monie savings review
Monie offers 5% APY on deposits, but funds aren’t insured and the interface is buggy.
Covid test stocks
We’ve rounded up stats on some of the most popular COVID test stocks, along with information on how they compare and how to invest.
Is Berkshire Hathaway the next $1 trillion stock?
Buffett’s Berkshire Hathaway may now be on its way to becoming the next trillion-dollar company.
Tesla roars into 2022 after December drop
Record vehicle deliveries cause the Tesla stock price to move close to all-time highs.
How to buy Affinia Therapeutics (AFTX) stock when it goes public
Everything we know about the Affinia Therapeutics IPO, plus information on how to buy in.
How to buy Austin Gold (AUST) stock when it goes public
Everything we know about the Austin Gold IPO, plus information on how to buy in.
How to buy VinFast stock when it goes public
Everything we know about the VinFast IPO, plus information on how to buy in.
How to buy Nexalin Technology (NXL) stock when it goes public
Everything we know about the Nexalin Technology IPO, plus information on how to buy in.
How to buy Specialty Building Products (SBP) stock when it goes public
Everything we know about the Specialty Building Products IPO, plus information on how to buy in.
Ask an Expert